New implant aims to silence snoring and save lives
NCT ID NCT07331285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a device called the Genio® System for people with moderate to severe obstructive sleep apnea who cannot use CPAP machines. The device is implanted and stimulates the tongue to keep the airway open during sleep. Researchers will track how well it reduces breathing pauses and oxygen drops over five years in 229 adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Genio® System 2.1 (implantable device that stimulates the tongue to keep the airway open during sleep)
- What this could lead to
- If successful, this could provide a long-term treatment option for people with obstructive sleep apnea who cannot tolerate standard CPAP therapy.
- What could go wrong
- This is a single-arm study (no comparison group), so results may be less definitive. Risks include device-related side effects or the therapy not working for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 229 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects diagnosed with moderate to severe obstructive sleep apnea (OSA) who are intolerant to or failed/refused PAP treatments.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Have an apnea-hypopnea index (AHI) greater than or equal to 15 and less than or equal to 65, measured on a full-night PSG performed no earlier than 2 years prior to enrollment (AHI4 and ODI4 available). 2. Be adults 22 years of age and older. 3. Have been confirmed to have failed, not tolerated, or be ineligible to be treated with current standard of care treatments for moderate to severe OSA. 4. Have pursued insurance pre-authorization for Genio® Therapy, recognizing that pre-authorization does not ensure payment, or demonstrate willingness to assume any out-of-pocket costs. The sponsor will not be responsible for treatment-related charges. 5. Agree to participate in the study and voluntarily sign and date an informed consent form. 6. Be willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits, evaluation procedures and questionnaires for the whole duration of the trial. 7. Have a result of a Drug- Induced Sleep Endoscopy (DISE), no earlier than 2 years prior to enrollment. Exclusion Criteria: 1. Combined central and mixed apnea-hypopnea index (AHI) greater than or equal to 25% of the total AHI. 2. Any functional or structural problem, medical illness or condition that would prevent or interfere with implantation, activation or continued use of the Genio® Therapy. 3. Have an implantable device which may be susceptible to unintended interaction with the Genio® System 2.1. 4. Women who are pregnant, planning to become pregnant or breastfeeding. 5. Any condition or procedure that has compromised neurological control of the upper airway. 6. Be part of the populations for which the safety and effectiveness of the Genio® System 2.1 has not been fully assessed: 1. Patients below 22 or above 75 years of age. 2. Patients with a Body Mass Index (BMI) above 32 kg/m2. 3. Patients with an Apnea Hypopnea Index (AHI) below 15 or over 65 events/hr. 4. Patients with Complete Concentric Collapse (CCC) at the soft palate level.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Nyxoah, Inc
NOT_YET_RECRUITINGSummit, New Jersey, 07901, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
PharmaDev Clinical Research Institute, LLC
RECRUITINGMiami, Florida, 33176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does concentrating change your breathing? study probes Brain-Breath link in opioid users
- Can software read sleep studies as well as a specialist?
- Monthly shot aims to quiet sleep apnea and shed pounds
- Can light therapy shrink tonsils and ease Kids' sleep apnea?
- Breathing brief Low-Oxygen bursts may boost sleep apnea treatment
- Can adding ketamine to propofol improve sleep apnea scans?